Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses

Area of Science:

• Virology
• Vaccinology
• Molecular Biology

Background:

• Traditional vaccine development faces challenges in achieving rapid, broad-spectrum protection.
• Nucleic acid vaccine platforms, including mRNA and DNA vaccines, have shown promise but often require multiple doses.
• Live-attenuated vaccines offer high immunogenicity but can pose safety concerns.

Purpose of the Study:

• To review the novel single-dose immunogenic DNA (iDNA) vaccine platform.
• To highlight the mechanism and advantages of iDNA vaccines for viral diseases.
• To assess the potential of iDNA vaccines for epidemic preparedness.

Main Methods:

• Review of existing literature on iDNA vaccine technology.
• Analysis of iDNA vaccine application in flavi- and alphavirus development.
• Comparison of iDNA vaccines with other nucleic acid and live-attenuated vaccines.

Main Results:

• iDNA vaccines use plasmid DNA to initiate replication of live-attenuated viruses in vitro or in vivo.
• Single-dose iDNA vaccination elicits a robust immune response and protection against pathogenic viruses.
• The iDNA platform combines advantages of reverse genetics, DNA immunization, and live-attenuated vaccine immunogenicity.

Conclusions:

• iDNA vaccines represent a novel class of immunogenic DNA vaccines encoding entire live-attenuated viruses.
• This platform offers enhanced safety and immunogenicity, surpassing single-dose efficacy compared to other nucleic acid vaccines.
• iDNA vaccines hold significant potential for improved epidemic preparedness and vaccine development.